Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 14, 2010	4 Stocks We're Buying As part of our "11 O'Clock Stock" series, we like Domino's Pizza, IBM, Teva Pharmaceuticals, and Take-Two Interactive.
The Motley Fool August 13, 2010 Eric Bleeker	5 Stocks We're Buying What The Motley Fool's buying as part of the "11 O'Clock Stock" series.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool November 9, 2010 Eric Bleeker	Portfolio Checkup: 3 Stocks Soaring, 3 Stocks Sagging Checking in on the "11 O'Clock Stock" portfolio from July, in which Motley Fool analysts picked 50 stocks over 50 weekdays.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool September 8, 2010 Ron Gross	Today's Buy Opportunity: Domino's Pizza Do you love pizza? Well, then Domino's Pizza may be an investment that's as tasty as a fresh made-to-order slice of pie.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool August 10, 2010	Why We're Buying Annaly Capital While risks such as Fannie Mae and Freddie Mac reform loom on Annaly's horizon, looking at its price-to-book multiple of 1.0, near-the-bottom of the stock's historical range, and its 15.6% dividend yield, Annaly is a good bet today.
The Motley Fool June 10, 2011 Matt Koppenheffer	Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio?
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool January 23, 2008 Brian Orelli	Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash.
The Motley Fool August 8, 2011 Ilan Moscovitz	What You Need to Know About Annaly Capital Mortgage REITs are popular with many investors right now for the high dividend yields they currently provide. Sporting a dividend yield of 14.9%, Annaly Capital is certainly no exception.
The Motley Fool May 11, 2005 Mike Cianciolo	Domino's Delivers The pizza delivery leader answers Papa's challenge. Investors may want to make room for some pizza.
The Motley Fool August 11, 2010 Tim Hanson	Today's Buy Opportunity: National Bank of Greece Why we are purchasing shares of National Bank of Greece.
The Motley Fool August 9, 2010 Jordan DiPietro	Today's Buy Opportunity: Telefonica Why today's "11 O'Clock Stock" is Telefonica.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool July 28, 2011 Cindy Johnson	Add It All Up: IBM Is Cheap Diversified businesses that are tough to value can be great values.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.
The Motley Fool October 25, 2005 Nathan Parmelee	Domino's Really Does Deliver The pizza chain tallies yet another solid quarter of growth. Investors, take note.
The Motley Fool July 27, 2011	Allegiant Travel Company Earnings Preview Allegiant Travel Company will unveil its latest earnings on Monday, August 1.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool April 15, 2005 Rick Aristotle Munarriz	IBM Sings the Blue IBM fails to live up to expectations during its seasonally quiet first-quarter showing. Investors have been patient for an excruciatingly long time. Results need to happen sooner rather than later for IBM.
The Motley Fool September 7, 2010 Eric Bleeker	Today's Buy Opportunity: IBM Today's Motley Fool 11 O'Clock Stock pick gets the job done.
The Motley Fool June 9, 2010	Is IBM a Buy? While other tech companies -- such as Apple -- take a lot of heat for hoarding cash, IBM leverages its balance sheet better than any other tech company.
Pharmaceutical Executive October 1, 2006 Joanna Breitstein	"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival.
The Motley Fool July 20, 2006 Ryan Fuhrmann	Big Boy Blue What will it take for IBM to achieve its former glory? While investors wait for things to turn around, they're receiving an OK dividend yield of 1.6%.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool January 18, 2012 John Maxfield	Does Annaly Have Hidden Credit Risk? A close look at the mortgage REIT giant reveals a less obvious type of risk exposure.
The Motley Fool August 3, 2010 Anand Chokkavelu	3 Dividend Stocks to Consider Before Buying Annaly Capital If you like Annaly Capital's dividend, you may like these 3 better.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool May 11, 2011 Jared Cummans	Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool February 8, 2007 Emil Lee	Benign Yield Curve Environment Helps Annaly This beat-up REIT had a decent quarter.
The Motley Fool April 5, 2011 Brian Orelli	Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
The Motley Fool April 28, 2010 Jordan DiPietro	Note to the EU: Time Is Running Out The EU only has so long before the entire stack of dominoes fall.
The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.